Company news
Nanexa Ab (OMXSTO:NANEXA) news
Nanexa Ab news releases on 6ix. Latest, Sep 25, 2026: Nanexa and Novo enter into EUR 1.165 billion global license and collaboration agreement for long-acting…
Press releases & updates
Nanexa and Novo enter into EUR 1.165 billion global license and collaboration agreement for long-acting injectables
September 25, 2026
Nanexa publishes interim report for April - June 2026
August 27, 2026
Nanexa publishes interim report for January-March 2026
April 29, 2026
Nanexa resolves on set-off of outstanding loan
April 28, 2026
Nanexa announces exercise of warrants
April 2, 2026
Nanexa publishes annual report for 2025
March 26, 2026
Nanexa publishes year-end report and Q4 report 2025
February 19, 2026
Nanexa Announces Breakthrough Preclinical Data Demonstrating Exceptional Pharmacokinetic Profile for Monthly Semaglutide Formulation
January 27, 2026
Nanexa and Moderna enter into license and option agreement for the development of PharmaShell®-based products
December 10, 2025
Nanexa publishes interim report for January-September 2025
November 6, 2025
Nanexa AB changes Certified Adviser to Tapper Partners AB
October 1, 2025
Nanexa receives Japanese patent approval for specific PharmaShell structure
September 22, 2025
Nanexa publishes interim report for January-June 2025
August 27, 2025
Nanexa Signs Continuation of Feasibility Agreement with Major Pharmaceuticals Company to Investigate PharmaShell® Long-Acting Formulations in a Multi-Billion USD Market
August 8, 2025